

Xpert[®] Ebola

REF GXEBOLA-CE-10
GXEBOLA-CE-50

Trademark, Patents and Copyright Statements

Cepheid[®], the Cepheid logo, GeneXpert[®], Xpert[®], and Xpertise[™] are trademarks of Cepheid.

Windows[®] is a trademark of Microsoft Corporation.

Armored RNA[®] is a patented technology jointly developed by Asuragen Inc. and Cenetron Diagnostics, LLC under U.S. Patent Nos. 5,677,124, 5,919,625, 5,939,262 and other patents pending.

THE PURCHASE OF THIS PRODUCT CONVEYS TO THE BUYER THE NON-TRANSFERABLE RIGHT TO USE IT IN ACCORDANCE WITH THIS PACKAGE INSERT. NO OTHER RIGHTS ARE CONVEYED EXPRESSLY, BY IMPLICATION OR BY ESTOPPEL. FURTHERMORE, NO RIGHTS FOR RESALE ARE CONFERRED WITH THE PURCHASE OF THIS PRODUCT.

Copyright © Cepheid 2016. All rights reserved.



Cepheid AB
Röntgenvägen 5
SE-171 54 Solna
Sweden

Xpert[®] Ebola

For *in vitro* diagnostic use only.

1 Proprietary Name

Xpert[®] Ebola

2 Common or Usual Name

Xpert Ebola Assay

3 Intended Use

The Xpert Ebola Assay is a real-time reverse transcription polymerase chain reaction (RT-PCR) test intended for the qualitative detection of RNA from the Ebola Zaire virus (detected in the West Africa outbreak in 2014) in EDTA venous whole blood, peripheral blood from finger-stick, or buccal swab from individuals with signs and symptoms of Ebola Virus Disease (EVD) in conjunction with epidemiological risk factors.

Testing with the Xpert Ebola Assay should not be performed unless the individual meets clinical and epidemiological criteria for testing of suspected cases.

Results are for the presumptive identification of Ebola Zaire virus. The definitive identification of Ebola Zaire virus infection requires additional testing and confirmation procedures in consultation with public health or other authorities for whom reporting is required. The diagnosis of Ebola Zaire virus infection must be made based on history, signs, symptoms, exposure likelihood, and other laboratory evidence in addition to the identification of the Ebola Zaire virus.

Negative results do not preclude Ebola Zaire or other Ebola virus infections and should not be used as the sole basis for patient management decisions.

The level of Ebola virus present in blood and buccal swab from individuals with early systemic infection is unknown. Due to the difficulty in obtaining clinical specimens positive for Ebola, the Xpert Ebola Assay was evaluated with limited numbers of contrived specimens spiked with live Ebola Zaire virus or Ebola Zaire virus RNA. The assay has not been evaluated with blood and buccal swab from individuals with Ebola Zaire virus infection.

Notification of Public Health authorities: Local and national public health agencies should be notified of any patient suspected to have EVD. Confirmatory testing at the public health laboratory is necessary for positive detection results and may be necessary for negative detection results. Laboratories should consult with local or national public health officials on any positive or negative Xpert Ebola test result on the need for additional testing and appropriate transportation of specimens.

4 Summary and Explanation

Ebola virus disease (EVD) has occurred sporadically throughout West Africa for decades of outbreaks, but the current epidemic is the largest to date. As of March, 2015, over 24,000 individuals have been infected and over 10,000 have died as a result. EVD has now spread beyond Africa and to USA and Europe. The burden on healthcare workers in endemic areas is also significant with over 50% mortality rate.¹ Since the first discovery of Ebola virus in 1976, five Ebola species have been described: Zaire, Sudan, Côte d'Ivoire (Tai Forest), Bundibugyo and Reston Ebola virus. Among these Ebola virus species, Zaire Ebola virus has affected the widest geographic regions and is the cause of the recent outbreak.

The Xpert Ebola Assay uses RT-PCR technology to achieve high sensitivity for the qualitative detection of Zaire Ebola virus total nucleic acids in specimens.

To ensure accurate detection, the Xpert Ebola Assay is designed to detect glycoprotein (GP) gene and/or nucleoprotein (NP) gene. Each target is thought to be present in 100% of known Ebola Zaire virus.

5 Principle of the Procedure

The Xpert Ebola Assay is a rapid, automated test for qualitative detection of the Ebola Zaire virus. The assay is performed on the Cepheid GeneXpert Instrument Systems.

The GeneXpert Instrument Systems automate and integrate sample preparation, nucleic acid amplification, and detection of the target sequence in simple or complex samples using real-time reverse transcription PCR. The systems consist of an instrument, personal computer, and preloaded software for running tests and viewing the results. The systems require the use of single-use disposable GeneXpert cartridges that hold the real-time reverse transcription PCR reagents and host the real-time reverse transcription processes. Because the cartridges are self-contained, cross-contamination between samples is minimized. For a full description of the systems, refer to the appropriate *GeneXpert Dx Operator Manual* or *GeneXpert Infinity Operator Manual*.

The Xpert Ebola Assay includes reagents for the detection of Zaire Ebola virus total nucleic acids in specimens as well as a sample adequacy control and an internal control and to ensure adequate addition of sample, processing of the target and to monitor presence of inhibitor(s) in the reverse transcription and PCR reactions. The Probe Check Control (PCC) verifies reagent rehydration, PCR tube filling in the cartridge, probe integrity, and dye stability.

6 Reagents and Instruments

6.1 Materials Provided



The Xpert Ebola Assay kits contain sufficient reagents to process 10 or 50 specimens or quality control samples. The kits contain the following:

GeneXpert Ebola Assay Cartridges with Integrated Reaction Tubes

- Bead 1, Bead 2, and Bead 3 (freeze-dried)
- Rinse Reagent
- Elution Reagent
- Binding Reagent

10 per kit

- 1 of each per cartridge
- 0.5 mL per cartridge
- 2.0 mL per cartridge
- 2.0 mL per cartridge

50 per kit

- 1 of each per cartridge
- 0.5 mL per cartridge
- 2.0 mL per cartridge
- 2.0 mL per cartridge

Ebola Sample Reagent (Sample Reagent)

- Lysis Reagent (Guanidinium Thiocyanate)

1 bag of 10

- 10 x 2.5 mL per bottle

5 bags of ten

- 50 x 2.5 mL per bottle

Disposable 1 mL Transfer Pipettes

10 per kit

50 per kit

CD

1 per kit

1 per kit

Note Safety Data Sheets (SDS) are available at www.cepheidinternational.com under the **SUPPORT** tab.

7 Storage and Handling



- Store the Xpert Ebola Assay cartridges and reagents at 2–28 °C.
- Do not use any reagents that have become cloudy or discolored.
- Do not use a cartridge that has leaked.

8 Materials Required but Not Provided

- GeneXpert Dx System or GeneXpert Infinity Systems (catalog number varies by configuration): GeneXpert Instrument, computer with proprietary GeneXpert Software Version 4.4a or higher, Xpertise 6.2 or higher, barcode scanner, and operator manual
- Printer: If a printer is required, contact Cepheid Technical support to arrange for the purchase of a recommended printer.
- Disposable Swabs (catalog # SWAB/E-50)
- Vortex
- Chlorine Bleach

9 Warnings and Precautions



- For *in vitro* diagnostic use only.
- Treat all biological specimens, including used cartridges, as if capable of transmitting infectious agents. Because it is often impossible to know which might be infectious, all biological specimens should be treated with standard precautions. Guidelines for specimen handling are available from the U.S. Centers for Disease Control and Prevention and the Clinical and Laboratory Standards Institute.
- Local, state, and national public health agencies should be notified of any patient suspected to have Ebola Virus Disease (EVD). Confirmatory testing at the public health laboratory is necessary for positive detection results and may be necessary for negative detection results. Laboratories should consult with local or national public health officials on any positive detection OR no detection (negative) EVD test result on the need for additional testing and appropriate transportation of specimens.
- Consult your institution's environmental waste personnel on proper disposal of used cartridges and unused reagents. Check state, territorial, or local regulations as they may differ from national disposal regulations. The material may exhibit characteristics of hazardous waste requiring specific disposal requirements. Institutions should check their hazardous waste disposal requirements.
- All results should be interpreted by a trained professional in conjunction with review of the patient's clinical signs and symptoms and history.
- Use of this assay should only be for trained personnel.
- When processing more than one sample at a time, open only one cartridge; add the Sample Reagent-treated sample and close the cartridge before processing the next sample. Change gloves between samples
- Wear protective disposable gloves, laboratory coats and eye protection when handling specimens and reagents. Wash hands thoroughly after handling specimens and test reagents.
- Follow your institution's safety procedures for working with chemicals and handling biological samples.
- Do not substitute Xpert Ebola Assay reagents with other reagents.
- Do not open the Xpert Ebola Assay cartridge lid except when adding the Sample Reagent-treated sample.
- Do not use a cartridge if it appears wet or if the lid seal appears to have been broken.
- Do not use a cartridge that has been dropped after removing it from the packaging.
- Do not shake the cartridge. Shaking or dropping the cartridge after opening the cartridge lid may yield invalid results.
- Do not use a cartridge that has a damaged reaction tube.
- Each single-use Xpert Ebola Assay cartridge is used to process one test. Do not reuse spent cartridges.
- The single-use disposable pipette is used to transfer one specimen. Do not reuse spent disposable pipettes.
- The single-use disposable swab is used to collect and/or transfer one specimen. Do not reuse spent disposable swabs.
- Store the Xpert Ebola Assay kit at 2–28 °C.



Note

Before starting, remove the bottle containing the Sample Reagent from the kit and allow to adjust to room temperature. See Figure 1. If the bottle has not been stored in an upright position, make sure the buffer is settled in the bottom by giving the bottle a firm shake.

Note

Wear disposable gloves. Label the Sample Reagent bottle with the specimen identification.

10 Chemical Hazards



Cartridge and Reagent

- Contains Guanidinium thiocyanate
- Signal Word: Warning
- Hazard Class: Acute Toxicity 4
- Hazard Statements: H302: Harmful if swallowed, H316: Causes mild skin irritation, H320: Causes eye irritation, H402: Harmful to aquatic life, EUH301: Contact with acids liberates toxic gas
- Precautionary Statements:
 - **P264:** Wash hands thoroughly after handling.
 - **P280:** Wear protective gloves/eye protection/face protection.
 - **P273:** Avoid release to the environment.
 - **P302+P352:** IF ON SKIN: Wash with plenty of soap and water.
 - **P305+P351+P338:** IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
 - **P312:** Call a POISON CENTER or physician if you feel unwell.
 - **P501:** Dispose of contents/container to location in accordance with local and regional/national/international regulations.

11 Specimen Collection, Transport, and Storage

11.1 Whole Blood Collection



Collect whole blood specimens by venipuncture in EDTA tubes per the manufacturer's instructions for use. A minimum of 100 µL of whole blood is required for the Xpert Ebola Assay. Alternatively, use the swab (SWAB/E-50) to collect blood specimens from a finger-stick. Allow at least 2/3 of swab head to absorb blood. Immediately transfer the swab into the bottle containing the Sample Reagent (see Figure 1 and under sample preparation).

11.2 Buccal Swab

Use the swab (SWAB/E-50) to collect buccal swab specimens according to WHO guidance for Oral Swab Collection of Ebola Patients.* Avoid touching the swab tip with the gloves or against any surface. For living patients, have the patient open their mouth and immediately bring the swab tip to the inside of the cheek. Rub firmly with circular motions and solid pressure for at least 20 seconds with the entire swab head. For deceased patients, place the palm of your hand onto the chin and press down firmly to open the mouth slightly. Insert the swab into the side of the cheek and rub firmly with circular motions and solid pressure for at least 20 seconds with the entire swab head. Repeat for the other cheek if accessible.

*WHO reference number: WHO/EVD/Guidance/Lab/14.2

Important Immediately proceed with the sample preparation step to ensure that the Ebola virus becomes inactivated.

Note Wear disposable gloves. Label the Sample Reagent bottle with the specimen identification.

Sample Preparation Venous Whole Blood collected in EDTA-tubes: Open the lid of the Sample Reagent bottle. Transfer 0.1 mL blood by placing the swab (SWAB/E-50) in the EDTA tube and allow it to absorb blood for at least 5 seconds, transfer the sample by inserting the prepared swab into the Sample Reagent bottle (see Figure 1). Hold the swab by the stem and align the small groove against the rim of the bottle. Break off the swab by bending to one side. Alternatively, use an automatic pipette with filter barrier tips to transfer 0.1 mL blood from the EDTA tube.

Buccal Swab: Open the lid of the sample reagent bottle. Insert the prepared swab into the Sample Reagent (see Figure 1). Hold the swab by the stem and align the small groove against the rim of the bottle. Break off the swab by bending to one side.

Blood collected from finger-stick: Use the swab (SWAB/E-50) to collect blood from a finger-stick and allow it to absorb 0.1 mL blood. Ensure that at least 2/3 of the swab head is covered with blood, and transfer the sample by inserting the prepared swab into the Sample Reagent bottle (see Figure 1). Hold the swab by the stem and align the small groove against the rim of the bottle. Break off the swab by bending to one side.

Note Use sterile gauze to minimize risk of contamination.

Close the lid of the Sample Reagent bottle and mix the sample by vortex for 10 seconds. Let it incubate at room temperature for 20 minutes.




Figure 1. Xpert Ebola Assay Sample Reagent Bottle and Ebola Sample Collection Swab

11.3 Sample Transport and Storage



Transport Sample Reagent-treated samples to the testing laboratories for further processing in individual resealable bags according to WHO guidelines for transport of Ebola specimens, “How to safely collect blood samples from persons suspected to be infected with highly infectious blood-borne pathogens (e.g. Ebola)”. The Sample Reagent-treated blood samples may be stored for up to 72 hours at 2-8 °C and for up to 48 hours at a maximum of 28 °C or for up to 24 hours at a maximum of 35 °C. The Sample Reagent-treated buccal swab samples may be stored for up to 72 hours at 2-8 °C and for up to 24 hours at a maximum of 28 °C.

12 Procedure

12.1 Preparing the Cartridge

Note There is a thin plastic film that covers the inner ring of the ports of the test cartridge. This film should not be removed.

Important Start the test within 30 minutes of adding the sample to the cartridge.

1. Wear protective disposable gloves.
2. Inspect the test cartridge for damage. If damaged, do not use.
3. Label the cartridge with the specimen identification.
4. Open the cartridge lid.

5. Use the 1 mL transfer pipette (see Figure 2) or automatic pipette with filter barrier tip to transfer 1 mL of the Sample Reagent-treated specimen into the sample chamber of the cartridge (see Figure 3). Do **NOT** pour the specimen into the sample chamber.




Figure 2. Xpert Ebola Assay 1 mL Transfer Pipette




Figure 3. Xpert Ebola Assay Cartridge (Top View)

12.2 Starting the Test

Important Before starting the test, make sure the Xpert Ebola Assay Definition File is imported into the software.

This section lists the basic steps for running the test. For detailed instructions, see the *GeneXpert Dx System Operator Manual* or the *GeneXpert Infinity System Operator Manual*, depending on the model that is being used.

1. Turn on the GeneXpert instrument system:
 - If using the GeneXpert Dx instrument, first turn on the instrument and then turn on the computer. The GeneXpert software will launch automatically or may require double-clicking the GeneXpert Dx software shortcut icon on the Windows® desktop.
 - or
 - If using the GeneXpert Infinity instrument, power up the instrument. The Xpertise software will launch automatically or may require double clicking the Xpertise software shortcut icon on the Windows desktop.
2. Log on to the GeneXpert Instrument System software using your user name and password.
3. In the GeneXpert System window, click **Create Test** (GeneXpert Dx) or click **Orders** and **Order Test** (Infinity).
4. Scan in the Patient ID (optional). If typing the Patient ID, make sure the Patient ID is typed correctly. The Patient ID is associated with the test results and is shown in the View Results window.
5. Scan or type in the Sample ID. If typing the Sample ID, make sure the Sample ID is typed correctly. The Sample ID is associated with the test results and is shown in the View Results window and all reports. The Scan Cartridge dialog box appears.

6. Scan the barcode on the Xpert Ebola Assay cartridge. The Create Test window appears. Using the barcode information, the software automatically fills the boxes for the following fields: Select Assay, Reagent Lot ID, Cartridge SN.
7. Click **Start Test** (GeneXpert Dx) or **Submit** (Infinity). Enter your password, if requested.
8. For the GeneXpert Infinity System, place the cartridge on the conveyor belt. The cartridge will be automatically loaded, the test will run, and the used cartridge will be placed into the waste container.

or

For the GeneXpert Dx Instrument:

- A. Open the instrument module door with the blinking green light and load the cartridge.
- B. Close the door. The test starts and the green light stops blinking. When the test is finished, the light turns off.
- C. Wait until the system releases the door lock before opening the module door. Then remove the cartridge.
- D. The used cartridges should be disposed in the appropriate specimen waste containers according to your institution's standard practices.

13 Viewing and Printing Results

This section lists the basic steps for viewing and printing results. For more detailed instructions on how to view and print the results, see the *GeneXpert Dx System Operator Manual* or the *GeneXpert Infinity System Operator Manual*, depending on the instrument used.

1. Click the **View Results** icon to view results.
2. Upon completion of the test, click the **Report** button of the View Results window to view and/or generate a PDF report file.

14 Quality Control

CONTROL

Each test includes a Sample Adequacy Control (SAC), a Cepheid Internal Control (CIC) and Probe Check Control (PCC).

- **Sample Adequacy Control (SAC):** The SAC ensures that human cells have been added in the sample chamber. The SAC passes if it meets the validated acceptance criteria.
- **Cepheid Internal Control (CIC):** Ensures the sample was correctly processed. The CIC is an Armored RNA® in the form of a dry bead that is included in each cartridge to verify adequate processing of the sample virus. The CIC verifies that lysis of Ebola has occurred if the organism is present and verifies that the specimen processing is adequate. Additionally this control detects specimen-associated inhibition of the PCR reaction. The CIC should be positive in a negative sample and can be negative or positive in a positive sample. The CIC passes if it meets the validated acceptance criteria.
- **Probe Check Control (PCC, QC1, QC2):** Before the start of the reverse transcription PCR assay, the GeneXpert Instrument System measures the fluorescence signal from two of the probes (denoted as QC1 and QC2) to monitor bead rehydration, reaction-tube filling, probe integrity and dye stability. Because QC1 and QC2 are measured at the time of reverse transcription PCR step (prior to the real-time PCR step), growth curves are not available. The PCC passes if it meets the assigned acceptance criteria.
- **External Controls:** External controls should be used in accordance with local, state, and federal accrediting organizations' requirements as applicable.
- Negative venous whole blood specimens can be used as External Negative Controls to be run as patient specimens.
- For information on how to obtain optional external control materials, contact Technical Support at TechSupport@cepheid.com or www.cepheid.com under the **SUPPORT** tab.

15 Interpretation of Results

The results are interpreted automatically by the GeneXpert Instrument System from measured fluorescent signals and embedded calculation algorithms and are clearly shown in the View Results window (see Figure 4, Figure 5, Figure 6 and Figure 7). Possible results are shown in Table 1.

Table 1. Xpert Ebola Assay Results and Interpretation

Result	Interpretation
Ebola GP DETECTED, Ebola NP DETECTED or Ebola GP DETECTED, Ebola NP NOT DETECTED or Ebola GP NOT DETECTED, Ebola NP DETECTED See Figure 4, Figure 5 and Figure 6.	The EBOLA target nucleic acids are detected. <ul style="list-style-type: none"> • The EBOLA signal for both or one of the two nucleic acids target have a Ct within the valid range and endpoint above the minimum setting. • SAC: NA (not applicable); SAC is ignored because the EBOLA target amplification occurred. • CIC: NA (not applicable); CIC is ignored because the EBOLA target amplification occurred. • Probe Check: PASS; all probe check results pass.
Ebola GP NOT DETECTED, Ebola NP NOT DETECTED See Figure 7.	The EBOLA target nucleic acids are not detected. CIC meets acceptance criteria. <ul style="list-style-type: none"> • SAC: PASS; SAC has a Ct within the valid range and endpoint above the minimum setting. • CIC: PASS; CIC has a Ct within the valid range and endpoint above the minimum setting. • Probe Check: PASS; all probe check results pass.
INVALID	Presence or absence of the target nucleic acids cannot be determined. Repeat test according to instructions in Retest Procedure. <ul style="list-style-type: none"> • SAC: FAIL; SAC Ct is not within the valid range and the endpoint is below the minimum setting. • CIC: PASS; CIC has a Ct within the valid range and the endpoint above the minimum setting. • Probe Check: PASS; all probe check results pass. Or <ul style="list-style-type: none"> • SAC: PASS; SAC has a Ct within the valid range and the endpoint above the minimum setting. • CIC: FAIL; CIC Ct is not within the valid range and the endpoint is below the minimum setting. • Probe Check: PASS; all probe check results pass.
ERROR	Presence or absence of EBOLA nucleic acids cannot be determined. Repeat test according to the instructions in Retest Procedure. <ul style="list-style-type: none"> • EBOLA: NO RESULT • SAC: NO RESULT • CIC: NO RESULT • Probe Check: FAIL, all or one of the probe checks fail.

Table 1. Xpert Ebola Assay Results and Interpretation (Continued)

Result	Interpretation
NO RESULT	<p>Presence or absence of EBOLA target nucleic acids cannot be determined. Repeat test according to the instructions in Retest Procedure. A NO RESULT indicates that insufficient data were collected. For example, the operator stopped a test that was in progress.</p> <ul style="list-style-type: none"> • EBOLA: NO RESULT • SAC: NO RESULT • CIC: NO RESULT • Probe Check: NA (not applicable)

Note Assay screenshots are for example only and may vary from screenshots shown in this package insert. QC1 and QC2 in legends of Figure 4, Figure 5, Figure 6, and Figure 7 control for presence of probes (see Probe Check Control in Section 14, Quality Control); amplification curves are not generated.




Figure 4. Ebola GP DETECTED, Ebola NP DETECTED




Figure 5. Ebola GP DETECTED, Ebola NP NOT DETECTED




Figure 6. Ebola GP NOT DETECTED, Ebola NP DETECTED




Figure 7. Ebola GP NOT DETECTED, Ebola NP NOT DETECTED

16 Retests

16.1 Reasons to Repeat the Test

If any of the test results mentioned below occur, repeat the test according to the instructions in Section 15.2 Retest Procedure.

- An **INVALID** result indicates one or more of the following
 - The control CIC failed.
 - The sample was not properly processed or PCR is inhibited.
 - The control SAC failed.
 - The added sample volume was insufficient.
- An **ERROR** result indicates that the assay was aborted. Possible causes include: the reaction tube being filled improperly, a reagent probe integrity problem was detected, because the maximum pressure limit was exceeded.
- A **NO RESULT** indicates that insufficient data were collected. For example, the operator stopped a test that was in progress, or a power failure occurred.

16.2 Retest Procedure

For retest of a **NO RESULT**, **INVALID**, or **ERROR** result, use a new cartridge (do not re-use the cartridge) and new reagents.

1. Remove a new cartridge from the kit.
2. See Section 12.1, Preparing the Cartridge, and Section 12.2, Starting the Test.

17 Performance Characteristics

17.1 Limit of Detection for Whole Blood

The limit of detection (LoD) of the Xpert Ebola Assay was estimated for Ebola Zaire RNA and for live Ebola Zaire virus. Testing was performed with three dilution panels each tested using one reagent kit lot. Viral RNA purified from Ebola Zaire Mayinga virus obtained from Public Health Agency of Sweden was diluted in a mixture of Sample Reagent and whole blood and the live Ebola virus 2014/Gueckedou-C05 and 2014/Gueckedou-C07 were each diluted in EDTA whole blood. In total, 20 RNA replicates and 4 live virus replicates per level and specimen were tested. The LoD using RNA was estimated as the lowest concentration of target Ebola Zaire RNA that could be reproducibly distinguished from negative samples with 95% probability using Probit analysis. The claimed LoD for Mayinga RNA was confirmed by analyzing at least twenty replicates diluted to the estimated LoD concentration using three reagent lots of the Xpert Ebola assay. 95% of the replicates were positive in one reagent lot and 100% in two reagent lots. The estimated LoD of live virus was confirmed as the lowest concentration of plaque forming unit (PFU) per mL EDTA whole blood at which at least 19 out of 20 replicates were positive. The results for Ebola Zaire RNA and live virus are shown in Table 2 and Table 3.

Table 2. Limit of Detection for Ebola Zaire RNA for Xpert Ebola Assay Using Probit Regression

Specimen	Nominal Concentration (copies/mL)	Total Replicates (N)	Total Positives (N)	Positivity Rate (%)	LoD with 95% Probability Estimated by Probit (95% Confidence Interval)
Ebola Zaire Mayinga RNA	700	20	20	100	232.4 copies/mL (95% CI 163.1-301.6)
	300	20	20	100	
	150	20	13	65	
	75	20	12	60	
	30	20	9	45	
	15	20	5	25	

Table 3. Numbers of Positive Replicates Per Level for Ebola Zaire Makona-Gueckedou 07 and 05 Virus in EDTA-WB and Confirmation of Limit of Detection

Specimen	Nominal Concentration (PFU/mL)	Total Replicates (N)	Total Positives (N)	Positivity Rate (%)	Confirmation of LoD		
					Nominal Concentration (PFU/mL)	Total Replicates (N)	Total Positives (N)
Ebola Zaire Makona-Gueckedou 07 virus	50	4	4	100	1.0	20	20
	25	4	4	100			
	12.5	4	4	100			
	1	4	4	100			
	0.1	3	1	33			
	0.01	4	0	0			
Ebola Zaire Makona-Gueckedou 05 virus	0.13	4	4	100	0.13	20	20
	0.065	4	4	100			
	0.0325	4	3	75			
	0.01625	4	1	25			

17.2 Limit of Detection for Buccal Swabs

The limit of detection (LoD) for buccal swabs of the Xpert Ebola Assay was determined for Ebola Zaire RNA. One dilution panel consisting of eight members was prepared from one Ebola Zaire Mayinga RNA specimen and tested on one reagent lot. The dilution panel was prepared by spiking the Ebola RNA into a pool of swabs in SR in the range of approximately 0 to 1,000 Ebola RNA copies/swab. The LoD for buccal swabs using RNA was estimated using Probit analysis. The claimed LoD was confirmed by analyzing at least 20 replicates diluted to the estimated LoD concentrations using two reagent lots of the Xpert Ebola Assay. The claimed LoD is defined as the concentration at which 95% of at least 20 replicates per reagent lot are positive (Table 4). The LoD for the Xpert Ebola Assay using buccal swabs spiked with Ebola Zaire Mayinga RNA is determined to be 350.0 copies/swab.

Table 4. Limit of Detection for Ebola Zaire RNA in Buccal Swabs for Xpert Ebola Assay Using Probit Regression and Confirmation of Limit of Detection

Specimen	Nominal Concentration (copies/swab)	Total Replicates (N)	Total Positives (N)	Positivity Rate (%)	LoD with 95% Probability by Probit (99.9% Confidence Interval)	Confirmation of LoD			
						Nominal Concentration (copies/swab)	Reagent Lot	Total Replicates (N)	Total Positives (N)
Ebola Zaire RNA in Buccal Swabs	600	20	20	100	250.0 copies/swab (99.9% CI 149.3-350.0)	350	1	20	20
	400	20	19	95					
	200	20	18	90					
	100	20	18	90					
	50	20	5	25		2	20	20	
	25	20	5	25					
	12.5	20	1	5					
	0	20	0	0					

Sample Type Equivalence (venous EDTA whole blood and whole blood from finger-stick)

Using the Xpert Ebola Assay, equivalent performance for the two different sample types venous EDTA whole blood and finger-stick whole blood was demonstrated with specimens from twenty healthy individuals. Blood from venipuncture was collected in an EDTA-tube and transferred to the Sample Reagent bottle, whereas the blood collected from a finger-stick was immediately placed in the Sample Reagent. Both sample types were spiked with Ebola Mayinga RNA at 1,500 copies/mL and the analysis was done side-by-side. Equivalent performance between the sample types was shown.

Linear Range

The linearity of the Xpert Ebola Assay was determined for the Ebola GP and NP targets by analysis of a six member panel prepared with serial dilutions of Ebola Mayinga RNA specimen ranged from 3×10^2 to 1×10^7 copies/mL whole blood. Each panel member was analyzed in replicates of six using one reagent lot. The results are shown in Figure 8 and 9 and demonstrate that the assay is linear within a range of 3×10^2 to 1×10^7 copies/mL with an R^2 value (which is the product of a standard curve) of 0.99 for the Ebola GP target and 0.98 for the Ebola NP target.




Figure 8. Linearity of the Xpert Ebola GP Target




Figure 9. Linearity of the Xpert Ebola NP Target

17.3 Analytical Reactivity (Inclusivity)

The analytical reactivity (inclusivity) of the Xpert Ebola was determined for four Ebola Zaire strains other than Mayinga that were available in the form of live Ebola virus or viral RNA. In addition, *in silico* analysis of all other, not tested, available sequences of Ebola Zaire strains was performed. The test samples were prepared by spiking each individual specimen into Ebola negative EDTA whole blood, or if RNA prepared from virus was used, into Ebola negative EDTA whole blood mixed with Sample Reagent (SR). Each specimen was tested in replicates of 20 and a negative control specimen, comprised of Ebola negative EDTA whole blood, was tested in replicates of three using one kit lot of reagents. The test results for Ebola positive specimens are presented in Table 5. All Ebola negative control specimens were reported **Ebola GP NOT DETECTED, Ebola NP NOT DETECTED**.

Table 5. Analytical Reactivity for the Xpert Ebola Assay

Ebola Zaire Strain	Specimen Type	Testing Concentration	Total Replicates (N)	Total Positives (N)	Positivity Rate (%)
Guinea	Live virus	1x LoD	20	20	100%
Ekron	Live virus	3x LoD	20	20	100%
Gabon	Live virus	3x LoD	20	20	100%
Kikwit	RNA	5x LoD	20	20	100%

In silico analysis was performed to predict the performance of the Xpert Ebola Assay in detection of all Ebola Zaire variant sequences available in GenBank; from the first Zaire sequence data published in 1976 to the sequences from the current West Africa outbreak. The two Xpert Ebola amplicon sequences derived from Zaire glycoprotein (GP) and nucleoprotein (NP) genes were each submitted to BLAST (NCBI). Also, all six Xpert Ebola oligo sequences were checked individually against a local database alignment containing all Ebola Zaire sequences available in GenBank. The analyses show that the Ebola Zaire NP and GP oligonucleotides completely match all Zaire sequences present in GenBank.

17.4 Analytical Specificity (Exclusivity)

The analytical specificity of the Xpert Ebola Assay was evaluated by testing non-Ebola viruses and bacteria and non-Zaire Ebola strains at clinically relevant levels. The specimens were prepared by spiking each individual organism into Ebola negative EDTA whole blood or if genomic RNA/DNA of the organism was used, into Ebola negative EDTA whole blood mixed with Sample Reagent. The analytical specificity test results are shown in Table 6 and Table 7. The analytical specificity of the Xpert Ebola Assay for the evaluated organisms is 100%.

Table 6. Analytical Specificity Determination for Xpert Ebola Assay, non-Zaire Ebola Positive Specimens

Organism	Specimen Type	Testing Conc. (Particle Conc. Used for Nucleic Acid Isolation)	Unit (ng or PFU/mL WB)	N	Positive Results	Negative Results
Ebola Ivory Coast	Nucleic acids	546 ^a	ng/mL	3	0	3
Ebola Reston	Nucleic acids	3.0x10 ⁵	PFU/mL	3	0	3

a. RNA concentration of the stock material

Table 7. Analytical Specificity Determination for Xpert Ebola Assay, non-Ebola Specimens

Organism	Specimen Type	Testing Conc. (Particle Conc. Used for Nucleic Acid Isolation)	Unit (ng or PFU/mL WB)	N	Positive Results	Negative Results
Chikungunya Virus (181/25)	Nucleic acids	2798 ^a	ng/mL	3	0	3
<i>Coxiella burnetii</i>	Nucleic acids	50	ng/mL	3	0	3
Crimean Congo Hemorrhagic Fever virus (Dubai)	Nucleic acids	3.4x10 ⁶	PFU/mL	3	0	3
Dengue virus (Type 2)	Nucleic acids	2.7x10 ⁶	PFU/mL	3	0	3
<i>Hemophilus influenzae</i>	Nucleic acids	50	ng/mL	3	0	3
Influenza virus A (H9N2)	Nucleic acids	1.0x10 ⁵	PFU/mL	3	0	3
Lassa virus (Pinneo)	Nucleic acids	5.7x10 ³	PFU/mL	3	0	3
Marburg (Angola)	Nucleic acids	2.6x10 ⁶	PFU/mL	3	0	3
Marburg (Angola)	Live virus	5.0x10 ^{4b}	PFU/mL	3	0	3
Marburg (Musoke)	Nucleic acids	6.0x10 ⁴	PFU/mL	3	0	3
Marburg (Musoke)	Live virus	5.0x10 ^{4b}	PFU/mL	3	0	3
Marburg (Ravn)	Nucleic acids	4.8x10 ⁵	PFU/mL	3	0	3
Mosquito	Nucleic acids	50	ng/mL	3	0	3
<i>Pseudomonas aeruginosa</i>	Nucleic acids	50	ng/mL	3	0	3
<i>Rickettsia conorii</i>	Nucleic acids	50	ng/mL	3	0	3
<i>Rickettsia prowazekii</i>	Nucleic acids	50	ng/mL	3	0	3
<i>Rickettsia typhi</i>	Nucleic acids	50	ng/mL	3	0	3
Rift Valley Fever virus (SA51)	Nucleic acids	7.5x10 ⁵	PFU/mL	3	0	3
<i>Salmonella bongori</i>	Nucleic acids	50	ng/mL	3	0	3
<i>Salmonella typhi</i>	Nucleic acids	50	ng/mL	3	0	3

Table 7. Analytical Specificity Determination for Xpert Ebola Assay, non-Ebola Specimens (Continued)

Organism	Specimen Type	Testing Conc. (Particle Conc. Used for Nucleic Acid Isolation)	Unit (ng or PFU/mL WB)	N	Positive Results	Negative Results
<i>Shigella flexneri</i> Type2	Nucleic acids	50	ng/mL	3	0	3
<i>Streptococcus pneumoniae</i>	Nucleic acids	50	ng/mL	3	0	3
Tick	Nucleic acids	50	ng/mL	3	0	3
Yellow fever (OBS-6745)	Nucleic acids	1.0x10 ⁶	PFU/mL	3	0	3
<i>Yersinia enterocolitica</i>	Nucleic acids	50	ng/mL	3	0	3
<i>Yersinia pestis</i>	Nucleic acids	50	ng/mL	3	0	3

- a. RNA concentration of the stock material
b. Testing concentration of live virus.

In silico analysis were performed to predict the risk of cross reactivity of the Xpert Ebola Assay Zaire target oligonucleotides (GP and NP) to non-Zaire Ebola viruses, as well as towards all the exclusivity disease pathogens listed in Table 7 and Table 8. The analyses show that the Xpert Ebola primer and probe sequences are specific and should not yield false positive Ebola Zaire results with the evaluated organisms.

Table 8. Analytical Specificity *In Silico* Analysis Organisms

Organism
Ebola Sudan-Boniface
Ebola Sudan-Bundibugyo
Ebola Sudan-Gulu
Adenovirus
<i>Borrelia recurrentis</i>
Enterovirus
Influenza virus B
<i>Leptospira</i> genus
Marburg (Ci67)
<i>Neisseria meningitidis</i>
<i>Plasmodium falciparum</i>
<i>Plasmodium malariae</i>
<i>Plasmodium ovale</i>
<i>Plasmodium vivax</i>
<i>Rickettsia africae</i>
Rotavirus
RSV
<i>Trypanosoma</i>
<i>Vibrio cholera</i>

17.5 Potentially Interfering Substances

The susceptibility of the Xpert Ebola Assay to interference by elevated levels of endogenous substances encountered in whole blood was evaluated. For endogenous substances, Ebola negative EDTA whole blood and Ebola positive EDTA whole blood spiked with the substances were tested. To prepare Ebola positive specimens, Ebola Zaire Mayinga RNA (2,500 copies/mL) was added to the Sample Reagent which then was mixed with EDTA whole blood spiked individually with each interfering substance. A total of five substances were evaluated at concentrations shown in Table 9. Six replicates of each specimen were tested using one reagent kit lot. Elevated levels of the endogenous substances listed in Table 9 were shown not to impact the assay specificity or interfere with the Ebola detection.

Table 9. Endogenous Substances and Concentration Tested

Endogenous Substances	Concentration Tested
Albumin	90.0 mg/mL
Bilirubin	0.300 mg/mL
Human DNA	4.0 µg/mL
Hemoglobin	5.0 mg/mL
Triglycerides	30.0 mg/mL

17.6 Contrived Clinical Specimens Testing

Performance characteristics of the Xpert Ebola Assay were evaluated using mock clinical specimens. Reported data from these mock clinical specimens were obtained under blind strategies. Due to the difficulty of obtaining clinical specimens from Ebola infected patients, mock specimens were prepared by spiking Ebola live virus or Ebola viral RNA into EDTA-whole blood (WB) specimens obtained from different Ebola negative individuals. The WB was spiked with Ebola virus or viral RNA in varying concentrations from near the LoD to high levels (up to 200x the limit of detection [LoD]). In addition, un-spiked EDTA-WB specimens from different individual negative donors were also tested. Specimens were blinded when tested with the Xpert Ebola Assay.

The positive percent agreement (PPA) for EBOV Mayinga RNA was 100.0% (50/50, [95% CI: 92.9-100.0]), for Makona-Gueckedou 05 live virus the PPA was 100.0% (50/50, [95% CI: 92.9-100.0]), and for Makona-Gueckedou 07 live virus the PPA was 84.0% (42/50, [95% CI: 71.5-97.1]). The negative percent agreement was 100.0% (50/50 [97.5% CI 92.9-100.0]) for each study. Table 10, Table 11, and Table 12 show the results for both the negative and the Ebola spiked specimens.

Table 10. Numbers of Positive and Negative Test Results for Ebola Zaire Mayinga RNA Spiked Specimens and Negative Control Specimens

Nominal Concentration	N	Positive Results		Negative Results
0	50	0		50
1xLoD	25	25		0
3xLoD	10	10		0
10xLoD	10	10		0
100xLoD	5	5		0
				95% CI
Positive Percent Agreement		50/50	100%	92.9%-100%
Negative Percent Agreement		50/50	100%	92.9%-100%

Table 11. Numbers of Positive and Negative Test Results for Ebola Makona-Gueckedou 05 Virus Spiked Specimens and Negative Control Specimens

Nominal Concentration	N	Positive Results		Negative Results
0	50	0		50
1xLoD	25	25		0
3xLoD	10	10		0
10xLoD	10	10		0
100xLoD	5	5		0
				95% CI
Positive Percent Agreement		50/50	100%	92.9%-100%
Negative Percent Agreement		50/50	100%	92.9%-100%

Table 12. Numbers of Positive and Negative Test Results for Ebola Makona-Gueckedou 07 Virus Spiked Specimens and Negative Control Specimens

Nominal Concentration	N	Positive Results		Negative Results
0	50	0		50
2xLoD	25	21		4
6xLoD	10	10		0
20xLoD	10	6		4
200xLoD	5	5		0
				95% CI
Positive Percent Agreement		42/50	84.0%	71.5%-97.1%
Negative Percent Agreement		50/50	100%	92.9%-100%

Investigation of the difference in the PPA results for the contrived Ebola Makona-Gueckedou 07 Virus spiked specimens (Table 12) compared to the other two contrived sets (Table 10 and Table 11) of specimens showed inconsistencies in specimen preparation. Swabs were not completely immersed in the specimens containing the whole blood specimens spiked with Ebola Makona-Gueckedou 07 limiting the amount of sample available for testing. The testing for the contrived Ebola Makona-Gueckedou 07 Virus spiked specimens was repeated using 50 individual WB specimens at the correct final concentrations and volume for each specimen. Table 13 shows the summary results at each concentration tested and the positive and negative percent agreement for the repeated study.

Table 13. Summary of Results and Positive and Negative Percent Agreement for Mock Clinical Specimens Spiked with Ebola Makona-Gueckedou 07 virus—Texas

Nominal Concentration	N	Positive Results		Negative Results
0	6	0		6
1xLoD	25	20		5
3xLoD	10	10		0
10xLoD	10	10		0
100xLoD	5	5		0
				95% CI
Positive Percent Agreement		45/50	90.0%	78.6%-95.7%
Negative Percent Agreement		6/6	100%	61.0%-100%

18 Virucidal Efficacy

Effectiveness of the Xpert Ebola Sample Reagent (SR) in inactivating the Ebola virus (EBOV) after 20 minutes incubation in SR was evaluated by adding 4.6×10^6 PFU live Ebola Zaire Guinea virus to 2.5 mL SR. Following the inactivation, the EBOV/SR mixture was subjected to dialysis using a Single-Use Rapid Equilibrium Dialysis device. Control for the inactivation experiment was live Ebola Zaire Kikwit virus ($\sim 1 \times 10^7$ PFU/mL) diluted 10 times in complete AVL Lysis buffer and inactivated for 5 min at 90 °C. The live Zaire Guinea virus (4.6×10^6 PFU) served as the positive control. The virucidal efficiency of the SR was studied by adding the virus/SR mixture onto confluent Vero E6 cells and monitoring the cytopathic effect (CPE) over 2 passages (7 + 7 days) in replicates of three.

The Xpert Ebola SR completely inactivated the added EBOV virus and was shown to be 100% effective for up to 6 logs of EBOV.

19 Assay Limitations

- Negative test results do not preclude Ebola virus infection and should not be used as the sole basis for treatment or other patient management decisions
- All test results should be interpreted by a trained professional in conjunction with the patient's history and clinical signs and symptoms.
- This test has been evaluated for use with human whole blood and buccal swab specimens only.
- Specimens from patients who have received therapeutics or vaccines based on nucleic acid sequences derived from Ebola Zaire virus may exhibit false positive or other confounding test results.
- This test is a qualitative test and does not provide a quantitative value for the virus in the sample.
- Interpretation of results from the Xpert Ebola Assay must account for the possibility of false-positive and false-negative results.
- False positive results may occur from cross-contamination by target organism, their nucleic acids, or from PCR amplicon.
- Failure to follow assay procedures may lead to false results.
- Inhibitors present in the samples may lead to false-negative results.

20 References

1. WHO Ebola Situation Reports <http://apps.who.int/ebola/en/ebola-situation-reports>.

21 Cepheid Headquarters Locations

Corporate Headquarters	European Headquarters
Cepheid 904 Caribbean Drive Sunnyvale, CA 94089 USA	Cepheid Europe SAS Vira Solelh 81470 Maurens-Scopont France
Telephone: +1 408.541.4191	Telephone: +33 563 825 300
Fax: +1 408.541.4192	Fax: +33 563 825 301
www.cepheid.com	www.cepheidinternational.com

22 Technical Assistance













Before contacting Cepheid Technical Support, collect the following information:

- Product name
- Lot number
- Serial number of the instrument
- Error messages (if any)
- Software version and, if applicable, Computer Service Tag number

Region	Telephone	Email
US	+1 888.838.3222	TechSupport@cepheid.com
France	+33 563 825 319	Support@cepheideurope.com
Germany	+49 69 710 480 480	Support@cepheideurope.com
United Kingdom	+44 3303 332 533	Support@cepheideurope.com
South Africa	+27 861 22 76 35	Support@cepheideurope.com
Other European, Middle East and African countries	+33 563 825 319 +971 4 253 3218	Support@cepheideurope.com
Australia, New Zealand	+61 1800 107 884	Support@cepheideurope.com
Other countries not listed above	+1 408.400.8495	TechSupport@cepheid.com

Contact information for other Cepheid offices is available on our website at www.cepheidinternational.com under the **SUPPORT** tab. Select the **Contact Us** option.

23 Table of Symbols

Symbol	Meaning
	Catalog number
	<i>In vitro</i> diagnostic medical device
	CE marking – European Conformity
	Do not reuse
	Batch code
	Consult instructions for use
	Manufacturer
	Contains sufficient for <n> tests
	Control
	Temperature limitation
	Biological risks
	Warning



Cepheid AB
 Röntgenvägen 5
 SE-171 54 Solna
 Sweden

